Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma models
{{output}}
Chimeric antigen receptor (CAR) T cell therapy has reshaped the therapeutic landscape for multiple myeloma (MM), yet most patients treated with BCMA-targeted CAR T cells experience disease relapse. Consequently, we sought to determine if inhibition of CD28 sur... ...
